Pirfenidone, studied in 127 pts w/ CVD/CTD ILD, fibrotic interstitial pneumonia, chr hypersensitivity pneumonitis, & asbestoslung fibrosis. Pirefenidone had significantly less FVC% decline compared with placebo (p=0ยท043) https://t.co/H1s6ut4NhG
Links:
May-29-2021


